ICML 2023 | TNB-486: interim results of a CD19/CD3 T-cell engager in R/R follicular lymphoma
In this video, Ranjit Nair, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares an update from the early interim analysis of a Phase I study investigating TNB-486, a CD19/CD3 bispecific T-cell engager, in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL; NCT04594642). Dr Nair discusses the efficacy and safety data from patients with R/R follicular lymphoma (FL) who have failed two or more prior lines of therapy. Dr Nair highlights the design of this study, and then goes on to summarize the results, including the high overall response rate (ORR) observed in patients who reached the target dose. To conclude, Dr Nair comments on the toxicity profile of this agent, including rates of cytokine release syndrome (CRS), neurotoxicity, and cytopenias. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant or advisory role: AbbVie, Incyte, ScienciaCME
Other remuneration: Speaking: AbbVie, Incyte, ScienciaCME
